Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Postdialysis trumps predialysis SBP, PP for mortality prediction in haemodialysis

18 Aug 2020

Postdialysis systolic blood pressure (SBP) and pulse pressure (PP) predict all-cause and cardiovascular mortality in haemodialysis patients, a recent Japan study reports.

The study included 2,690 haemodialysis patients who were divided into five categories according to pre- or post-dialysis blood pressure (BP): systolic BP (SBP), diastolic BP (DBP), or pulse pressure (PP). The primary outcomes of interest were all-cause and cardiovascular mortality.

Participants were followed for a median of 2.7 years, during which time 495 and 193 all-cause and cardiovascular deaths were reported.

After adjusting for potential confounders, the likelihood of all-cause (hazard ratio [HR], 1.85, 95 percent confidence interval [CI], 0.95–3.60) and cardiovascular mortality (HR, 2.42, 95 percent CI, 0.92–6.38) appeared to be higher in patients with a predialysis SBP <100 vs 120–139 mm Hg, though statistical significance was not reached. Predialysis PP likewise showed no significant interaction with the outcomes.

In contrast, a U-shaped relationship was found for both postdialysis SBP and PP. Those with SBP <100 mm Hg (HR, 2.06, 95 percent CI, 1.37–3.10) and ≥160 mm Hg (HR, 1.42, 95 percent CI, 1.10–1.84), for instance, were significantly more likely to die of any cause than those with SBP 120–139 mm Hg. Postdialysis SBP shared a similar interaction with cardiovascular mortality.

Similarly, PP <50 mm Hg (HR, 1.89, 95 percent CI, 1.10–3.23) and ≥80 mm Hg (HR, 1.94, 95 percent CI, 1.24–3.05) conferred significantly elevated risks of cardiovascular mortality, as opposed to the middle group of PP 60–69 mm Hg. A similar U-shaped pattern was reported between all-cause mortality and PP.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.